Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human LOXL2 aa 750 to the C-terminus (C terminal) (Cysteine residue). The exact sequence is proprietary.
Database link: Q9Y4K0
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Our Abpromise guarantee covers the use of ab179810 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/200 - 1/1000. Predicted molecular weight: 87 kDa.|
Lane 1-3: 3min
Lane 4: 1min
Blocking/Diluting buffer and concentration 5% NFDM /TBST
MCF-7 lack LOXL2 expression (PMID: 19330836, PMID:12154058 and PMID: 27655685)